By Iffa Ipeh Jayyana 
A fundamental challenge in understanding and treating schizophrenia lies in its profound impact on cognitive processing, particularly the ability to integrate new information and update one’s perception of reality. This cognitive inflexibility can significantly impair decision-making and, over time, contribute to the profound detachment from reality that characterizes the disorder. Now, researchers at the Massachusetts Institute of Technology (MIT) have pinpointed a specific gene mutation that appears to play a critical role in this cognitive dysfunction, offering a promising new avenue for therapeutic intervention.
Unraveling the Genetic Basis of Cognitive Impairment
Schizophrenia, a chronic and severe mental disorder, affects approximately 1% of the global population. Its genetic underpinnings are complex, with heritability playing a significant role. Studies have shown that the risk of developing schizophrenia increases dramatically if a close relative is affected, rising to 10% for a parent or sibling and an astonishing 50% for identical twins. This strong genetic predisposition has prompted extensive research into identifying the specific genes and genetic variants that contribute to the disorder’s development and its multifaceted symptoms.
For years, large-scale genome-wide association studies (GWAS) have been instrumental in cataloging genetic variations associated with schizophrenia. These studies have identified over 100 gene variants that confer an increased risk. However, a substantial portion of these variants are located in non-coding regions of DNA, the vast stretches of genetic material that do not directly code for proteins. Interpreting the functional impact of these non-coding variants has proven to be a significant hurdle, leaving many genetic clues obscure.
To overcome this challenge, the research team at MIT employed whole-exome sequencing, a technique that focuses specifically on the protein-coding regions of the genome. This targeted approach allows scientists to identify mutations directly within genes that are responsible for producing essential proteins. By analyzing an extensive dataset comprising approximately 25,000 sequences from individuals diagnosed with schizophrenia and a control group of 100,000 individuals, the researchers successfully identified 10 genes where mutations demonstrably increase the risk of developing the disorder. This meticulous analysis laid the groundwork for their subsequent investigation into one of these key genes.
The GRIN2A Gene Mutation and its Impact on Brain Circuits
The focus of the groundbreaking new study, published in the prestigious journal Nature Neuroscience, is a gene known as grin2a. This gene is crucial for the production of a subunit of the NMDA receptor, a vital component of neuronal communication. NMDA receptors are activated by glutamate, a primary excitatory neurotransmitter in the brain, and are ubiquitously found on neurons, playing critical roles in learning, memory, and synaptic plasticity.
The researchers hypothesized that a mutation in the grin2a gene could disrupt the brain’s ability to effectively update its internal models of the world when presented with new information. This process, often referred to as belief updating or inferential reasoning, is fundamental to navigating a dynamic environment and making informed decisions.
To test this hypothesis, the scientists engineered laboratory mice to carry a specific mutation in the grin2a gene. While mice cannot articulate hallucinations or delusions, they can serve as valuable models for studying fundamental cognitive processes. The researchers focused on assessing the mice’s capacity to interpret and respond to new sensory information, a proxy for the cognitive flexibility often compromised in schizophrenia.
A Crucial Brain Circuit for Adaptive Decision-Making
The core of the problem, as explained by Guoping Feng, the James W. and Patricia T. Poitras Professor in Brain and Cognitive Sciences at MIT and a senior author on the study, lies in the disruption of a critical brain circuit. "If this circuit doesn’t work well, you cannot quickly integrate information," Professor Feng stated. "We are quite confident this circuit is one of the mechanisms that contributes to the cognitive impairment that is a major part of the pathology of schizophrenia."
The study, co-led by Michael Halassa, an associate professor of psychiatry and neuroscience at Tufts University, meticulously investigated the behavioral consequences of the grin2a mutation. Tingting Zhou, a research scientist at the McGovern Institute, and Yi-Yun Ho, a former MIT postdoctoral fellow, served as the lead authors, driving the experimental design and analysis.
Their research explored the long-standing hypothesis that psychosis, a hallmark of schizophrenia, might stem from an impaired ability to update one’s beliefs in the face of new evidence. As Dr. Zhou elaborated, "Our brain can form a prior belief of reality, and when sensory input comes into the brain, a neurotypical brain can use this new input to update the prior belief. This allows us to generate a new belief that’s close to what the reality is." In individuals with schizophrenia, however, this process appears to be skewed. "What happens in schizophrenia patients is that they weigh too heavily on the prior belief. They don’t use as much current input to update what they believed before, so the new belief is detached from reality."
Experimental Evidence: The Mouse as a Model for Cognitive Rigidity
To quantify this cognitive deficit, Dr. Zhou devised an ingenious task for the mice. They were trained to choose between two levers, each offering a different reward: one with a low reward (requiring six presses for a single drop of milk) and another with a high reward (yielding three drops per press). Initially, all mice, irrespective of their genetic makeup, gravitated towards the higher-reward lever.
However, the experimental conditions were subtly altered over time. The effort required to obtain the high reward gradually increased, while the low-reward lever remained constant. In a healthy, adaptive system, the mice would recognize this shift in value and adjust their behavior. When the effort for the high-reward option became comparable to or even greater than the low-reward option, neurotypical mice would strategically switch their preference to the more efficient choice and remain with it.
The mice carrying the grin2a mutation exhibited a markedly different response. They displayed a persistent tendency to switch back and forth between the levers for a prolonged period, delaying their commitment to the demonstrably more efficient choice. "We find that neurotypical animals make adaptive decisions in this changing environment," Dr. Zhou observed. "They can switch from the high-reward side to the low-reward side around the equal value point, while for the animals with the mutation, the switch happens much later. Their adaptive decision-making is much slower compared to the wild-type animals." This delayed adaptive decision-making directly mirrored the predicted cognitive inflexibility associated with the grin2a mutation.
Identifying the Neural Correlates: The Mediodorsal Thalamus
The researchers then employed sophisticated neuroimaging techniques, including functional ultrasound imaging and electrical recordings, to pinpoint the specific brain regions affected by the grin2a mutation. Their investigations converged on the mediodorsal thalamus, a critical hub within the brain’s intricate circuitry. This region plays a pivotal role in relaying information between the thalamus and the prefrontal cortex, forming a crucial thalamocortical circuit that is indispensable for executive functions, including decision-making, planning, and cognitive control.
Within the mediodorsal thalamus, the researchers observed distinct patterns of neural activity. Neurons in this region appeared to be actively tracking the changing values associated with the different lever choices. Furthermore, they noted discernible differences in neural firing patterns depending on whether the mice were actively exploring new options or had settled on a particular decision. This suggests that the grin2a mutation disrupts the neural mechanisms responsible for evaluating and updating the perceived value of outcomes based on new information.
Therapeutic Potential: Reversing Cognitive Deficits
Perhaps the most encouraging aspect of the study is the demonstration that the behavioral consequences of the grin2a mutation could be reversed. Utilizing optogenetics, a cutting-edge technique that allows researchers to control neuron activity with light, the team engineered neurons in the mediodorsal thalamus of the mutated mice to be responsive to light stimulation.
When these genetically modified neurons were activated, the mice exhibited a significant improvement in their decision-making abilities. Their behavior became more akin to that of their neurotypical counterparts, demonstrating a restored capacity for adaptive decision-making in the face of changing conditions. This finding provides compelling evidence that targeting this specific brain circuit holds substantial therapeutic promise for ameliorating cognitive symptoms associated with schizophrenia.
While the grin2a gene mutation itself is present in only a small fraction of individuals with schizophrenia, the researchers propose that the underlying dysfunction within the mediodorsal thalamus-prefrontal cortex circuit might represent a common mechanistic pathway for cognitive impairment across a broader spectrum of patients. This insight opens up exciting new possibilities for developing pharmacological interventions. The research team is actively working to identify specific molecular targets within this circuit that could be amenable to drug development.
Funding and Future Directions
This pivotal research was made possible through substantial funding from a consortium of leading scientific and philanthropic organizations, including the National Institute of Mental Health, the Poitras Center for Psychiatric Disorders Research at MIT, the Yang Tan Collective at MIT, the K. Lisa Yang and Hock E. Tan Center for Molecular Therapeutics at MIT, the Stelling Family Research Fund at MIT, the Stanley Center for Psychiatric Research, and the Brain and Behavior Research Foundation. Their collective investment underscores the critical importance and potential impact of this line of inquiry.
The implications of this study extend beyond the immediate findings. By providing a concrete link between a specific gene mutation, a key brain circuit, and a core cognitive deficit in schizophrenia, the research offers a refined framework for understanding the disorder. Future research will likely focus on translating these findings from animal models to human subjects, exploring whether similar circuit dysfunctions are present in a wider range of schizophrenia patients, and developing novel therapeutic strategies that specifically target the mediodorsal thalamus and its connections to the prefrontal cortex. The path to effective treatments for the cognitive dimensions of schizophrenia may have just become significantly clearer.